Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir 100-day versus 200-day prophylaxis in high-risk kidney transplant recipients
2005-002817-19Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Roche. Primary endpoint: Proportion of patients who develop CMV disease within the first 12 months post-transplant. Started Nov 2005; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2005-002817-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002817-19.